untitled

Size: px
Start display at page:

Download "untitled"

Transcription

1

2 ver.3.4 JT Actinidia chinensis Planch. 20 KIWI t Propionibacterium acnes

3 ver.3.4 JT - 2 quercitrin kaempferol 3-O-rhamnoside 3 1) quercitrin advanced glycation end product AGE 2) 3) quercitrin quercetin 4) NF-kappaB inos 5) 2. 6,7) 8,9) 10) kaempferol 3-O-rhamnoside OH OH HO O OH HO O O O OH O OH O OH OH CH 3 CH 3 H H OHOH OHOH quercitrin kaempferol 3-O-rhamnoside (quercetin 3-O-rhamnoside) 3. 2

4 ver.3.4 JT 1) Matsuda H., Ninomiya K., Shimoda H., Yoshikawa M. Hepatoprotective principles from the flowers of Tilia argentea (Linden) :Structure requirements of tiliroside and mechanisms of action. Bioorg. Med. Chem. 10, , (2002). 2) Hanamura T., Hagiwara T., Kawagishi H. Structural and functional characterization of polyphenols isolated from acerola (Malpighia emarginata DC.) fruit. Biosci. Biotechnol. Biochem. 69, , (2005). 3) Jeong CH, Shim KH. Tyrosinase inhibitor isolated from the leaves of Zanthoxylum piperitum. Biosci Biotechnol Biochem. 68, ,(2004). 4) Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Galvez J, Zarzuelo A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, whichinhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 35, , (2005). 5) Camuesco D, Comalada M, Rodriguez-Cabezas ME, Nieto A, Lorente MD, Concha A, Zarzuelo A, Galvez J. The intestinal anti-inflammatory effect of quercitrin is associated with aninhibition in inos expression. Br J Pharmacol. 143, , (2004). 6) Sanchez de Medina F, Vera B, Galvez J, Zarzuelo A. Effect of quercitrin on the early stages of hapten induced colonic inflammation in the rat. Life Sci. 70, , (2002). 7) Sanchez de Medina F, Galvez J, Romero JA, Zarzuelo A. Effect of quercitrin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther. 278, 771-9, (1996). 8) Lee HS. Rat lens aldose reductase inhibitory activities of Coptis japonica root-derivedisoquinoline alkaloids. J Agric Food Chem. 50, , (2002). 9) Matsuda H, Morikawa T, Toguchida I, Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductaseinhibitory activity. Chem Pharm Bull (Tokyo). 50, , (2002). 10) Galvez J, Crespo ME, Jimenez J, Suarez A, Zarzuelo A. Antidiarrhoeic activity of quercitrin in mice and rats. J Pharm Pharmacol. 45, 157-9, (1993). 3

5 ver.3.4 JT 5- DHT DHT DHT P. acnes P. acnes DHT P. acnes P. acnes P. acnes

6 ver.3.4 JT in vitro S-9 DHT 5- DHT quercitrin 5 quercitrin 5. 5-quercitrin (3.0mol) 5 mm Tris-HCl ph ml 1 ml NADPH (5 mg) (37) S-9, 1 5 ml MeOH DB-17, J&W He, 2 ml/min 250 in vitro P. acnes GAM P. acnes 5

7 ver.3.4 JT 6. P. acnes P. acnes GAM 3000 rpm10 min PBS PBS 3 4P. acnes S 390L25LP. acnes 50 mg/ml25l10l L L415 nm -LC -LC

8 ver.3.4 JT 7. -LC 2 -LC LC

9 ver.3.4 JT LC 11 ml SEBUMETER SM P50 mg/day 2 SEBUMETER SM810 in vitro NB1RGB 10. NB1RGB n=5 8

10 ver.3.4 JT (NB1RGB) -MEM 10%FCS100 units/ml 100g/mL /ml96 100L 10L 2 MTT P50 mg/day 4 ph

11 ver.3.4 JT ph 4 Corneometer

12 ver.3.4 JT ph ph ph ph ph P50 mg/day 4 SKIN CAST USB Microscope M2 NIH Image ph CORNEOMETER SM825 ph SKIN-pH-METER PH900 11

13 ver.3.4 JT in vitro quercitrin kaempferol 3-O-rhamnoside 15 quercitrin kaempferol 3-O-rhamnoside 15. quercitrinkaempferol 3-O-rhamnoside 70L/well0.3% L-DOPA70L/well 375 mushroom 1.6 units/ml70 L/well nm 12

14 ver.3.4 JT in vitro B16 quercitrin kaempferol 3-O-rhamnoside 16 quercitrin kaempferol 3-O-rhamnoside 16. B16 quercitrin kaempferol 3-O-rhamnoside B16 -MEM 510 /ml L 415 nm in vivo L 10 control 12 L 17 13

15 ver.3.4 JT :P<0.05 :P< n=4 Control 200 mg/kg 400 mg/kg 800 mg/kg

16 ver.3.4 JT Weiser-Maples 4 UV-B2000 mj/cm L 4 L* 6 4 L* P50 mg/day 4 Spectro Color Meter SE

17 ver.3.4 JT SOD 1,1-2- (DPPH) 20 SOD DPPH SOD DPPH

18 ver.3.4 JT 1% % 1 2 cm CORNEOMETER SM % 17

19 ver.3.4 JT in vitro LPS RAW264.7 PG E µg/mlpg E 2 quercitrin100 µg/ml kaempferol 3-O-rhamnoside100 µg/ml 22 * ** ** Ind.: ** ** quercitrin ** kaempferol 3-O-rhamnoside ** 22. PG E 2 quercitrinkaempferol 3-O-rhamnoside*: p<0.05, **: p<

20 ver.3.4 JT RAW mm 10%FCS100 units/ml100 µg/ml MEM cells/ml LPS Non (LPS ) 20 PG E 2 Prostaglandin E 2 EIA Kit in vivo 55 2% pontamine sky blue 5 1% 1%15 writhing writhing

21 ver.3.4 JT * ** * * ** ** 24. *: p<0.05, **: p<0.01 ddy5-6wp.o.55 2% pontamine sky blue i.v. 10 ml/kg 5 1% 10 ml/kg1%15 writhing 10 ml 590 nm Tanaka, J., Shan, S., Kasajima, N. and Shimoda, H. Suppressive effect of defatted kiwi fruit seed extract on acute inflammation and skin pigmentation. Food Sci. Technol. Res., 13 (4), ,

22 ver.3.4 JT n-3 6.2% 6.7% 2.3% 1.8% 15.6% 19.6% 15.8% 12.0% 59.8% 59.9% n-3 3 E E 1), 25, 47 (1991). 2), 150, 233 (1989). 3), 145, 911 (1988). 4) 44 2E-20P, (1989). 5) Tomeo A. C. et al., lipids, 30, (1995). 6) Kamat J. P. et al., Neurosci. Lett., 195, (1995). 21

23 ver.3.4 JT pH ph ph

24 ver.3.4 JT -WSP0.4%pH WSP 0.4pH g/50g 0.8g/50g 1 0.4g/50g 0.8g/50g 47.0g/50g 2 195kcal/50g g/50g 6.5mg/50g 0.02g/50g (+++) ; 9; 4;

25 ver.3.4 JT ICR 30 g mg/kg14 LD mg/kg LD mg/kg Ames Salmonella typhimuriumta100ta98 S9mix Ames µg/plate -P-WSP mg 1) 2) 3) 4) 5) 24

26 ver.3.4 JT -P -WSP -PC -WSPC 5kg -LC 5kg 16kg -P-WSP -PC-WSPC INCI Dextrin, Actinidia Chinensis (Kiwi) Seed Extract -LC BG INCI Butylene Glycol, Water, Actinidia Chinensis (Kiwi) Seed Extract INCIActinidia Chinensis (Kiwi) Seed Oil 25

27 ver.3.4 JT Actinidia chinensis Planch. 2.0 %5 mg/100g 5 mg/100g (HPLC ) 2.0 % ( Folin-Denis ) 10.0 % (1 g1052 ) (1) 10 ppm ( ) (2) 1 ppm () 110 /g () /g ( ) (BGLB) 75 % 25 % 100 % 26

28 ver.3.4 JT Actinidia chinensis Planch. 2.0 %5 mg/100g 5 mg/100g (HPLC ) 2.0 % ( Folin-Denis ) 10.0 % (1 g1052 ) (1) 10 ppm ( ) (2) 1 ppm () 110 /g () /g ( ) (BGLB) 75 % 25 % 100 % 27

29 ver.3.4 JT Actinidia chinensis Planch. 2.0 %5 mg/100g 5 mg/100g (HPLC ) 2.0 % ( Folin-Denis ) 10.0 % (1 g1052 ) (1) 10 ppm (2) (2) 1 ppm (3) /g () /g ( ) (BGLB) 75 % 25 % 100 % 28

30 ver.3.4 JT Actinidia chinensis Planch. 2.0 %5 mg/100g 5 mg/100g (HPLC ) 2.0 % ( Folin-Denis ) 10.0 % (1 g1052 ) (1) 10 ppm (2) (2) 1 ppm (3) /g () /g ( ) (BGLB) 75 % 25 % 100 % 29

31 ver.3.4 JT Actinidia chinensis Planch. 1,3-BG 30l3.5 ml 0.2 ml 0.4 ml ph (10%) (1) 10 ppm (2) (2) 1 ppm (3) /g () /g ( ) (BGLB ) BG 69 % 30 % 1 % 100 % 30

32 ver.3.4 JT Actinidia chinensis Planch. 0.5 (Y+10R) 50 (133.4mm) 55.0% GC HPLC (1) 10 ppm ( ) (2) 1 ppm () /g () ( ) (BGLB) 100 % 31

33 ver.3.4 JT Actinidia chinensis Planch g (Y+10R) 50 (133.4mm) 55.0% GC HPLC (1) 10 ppm (2) (2) 1 ppm (3) /g () ( ) (BGLB) 100 % 32

34 ver.3.4 JT TEL(0586) () FAX(0586) URL/ F TEL (03) FAX (03) P,WSP,PC,WSPC (P26-29)

35 ver.3.4 JT 34

untitled

untitled RYZA IL & FAT CHEMICAL C., LTD. SAKURA EXTRACT Ver.1.4MK Ver. 1.4MK 1) 1300 1929 1 Ver. 1.4MK Sakura 1-caffeoyl---D-glucopyranoside quercetin 3---D-glucopyranoside 1) :, 4, 11-22 (1995). 2 Ver. 1.4MK 3

More information

untitled

untitled ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504

More information

untitled

untitled er. 3.0SJ ver.3.0 SJ 3 2 1 ver.3.0 SJ 900 1200 () 400 2 ver.3.0 SJ OH OMe OMe O O O MeO O MeO OMe O O OMe O OMe OMe O O MeO O O H O O MeO OMe O H O OH OMe O CH 2 HO O O O O CH 3 OH HO OH OH HO OH O 1 3

More information

ver5.1 HS 1. ALPHA LIPOIC ACID () S S COOH HS 1. α - SH COOH - ( 1) CoA -( 2)- - --P80 (--WSP8-L1-WSPC8 -LC1) - 1

ver5.1 HS 1. ALPHA LIPOIC ACID () S S COOH HS 1. α - SH COOH - ( 1) CoA -( 2)- - --P80 (--WSP8-L1-WSPC8 -LC1) - 1 ORYZA OIL & FAT CHEMICAL CO., LTD. ALPHA LIPOIC ACID --P () --P80 () --WSP8 () --L1 () --PC () --PC80 () --WSPC8 () --LC1 () ver. 5.1HS ver5.1 HS 1. ALPHA LIPOIC ACID 16 3 31 0331009 - () 19 5 24 0524001

More information

untitled

untitled ORYZA CERAMIDE -PTPCDP8TP20CD -WSPWSP8 -LL0.8 -PCPC8PC20 -WSPCWSPC8 -LCLC0.8 Ver.13.0HS ORYZA CERAMIDE Ver.13.0HS 1. 2. 20 NMR 4 ( 1) 1 Ver.13.0HS HO CH 2 OH O O OH OH OH C CH CH H 2 NH C O R C H C H (CH

More information

untitled

untitled ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter

More information

untitled

untitled ver. 4.3 HS 14 1,620-6- 1) 2) 1 24% p- 45 1) Schwab D. et al., Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins. J. Pharmacol. Exp. Ther. 296, 91-8 (2001).

More information

untitled

untitled ORYZA OIL & FAT CHEMICAL CO., LTD. WHITE JELLY FUNGUS EXTRACT -P () Ver. 1.3SJ Ver. 1.3SJ 1. 3000 ph 1 Ver. 1.3SJ 1. 1 2. 3 2-1. 2-2. 2-3. 2-4. SOD 3. 7 3-1. in vitro 3-2. in vivo 3-3. in vivo 3-4. in

More information

10中西_他.indd

10中西_他.indd Streptomyces mobaraensis N N N Sm b Sm N N Sm Sm Sm ' ' Sm Sm ak K k K bk k K Sm Sm a b S. mobaraensis a b a b Sm b b bb b b Sm Sm S. lividans ab Sm ab Sm ab ab ab ab SmSm S. lividansab S. lividans ab

More information

まえがき

まえがき JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------

More information

untitled

untitled JAPANESE BUTTERBUR EXTRACT 1. 10 2 5 Petasites japonicus Japanese Butterbur (P. japonicus Maxim.)P. japonicus Maxim. var. giganteus 200 13 6,800 90% 40% 10 5 JA TNF- 1 in vivo 2 6 2 1) fukinoside 2) 1)

More information

g 51 52

g 51 52 10 12 A 12 C 12 13 13 13 13 16 16 18 18 18 23 23 23 23 23 A 24 25 25 26 28 28 30 32 38 38 41 42 43 10 43 11 45 48 48 120g 51 52 12 3 12 3 350g 120g 1 7 10 260g 90g 90g 30g 9 11 2 gg1 g 1 120g 10 1 12 6

More information

untitled

untitled E-mail: khatano@fms.saitama-u.ac.jp Tel & Fax: 048-858-3535 Toxin Virus Bacterium Glycolipid Glycoprotein Vero toxin (Stx1 and Stx2) Side view Bottom view H H H H N H Grobotriaosyl Ceramide (Gb 3 : Galα1-4Galβ1-4Glcβ-Cer)

More information

untitled

untitled FUCOXANTHIN HO OCOCH 3 HO O O ver.3.1 SJ FUCOXANTHIN 26 9 1 ver.3.1 SJ A 2 1-6 7-15 16-17 18 19 HO OCOCH 3 HO O O 1822 1) Maeda H, Tsukui T, Sashima T, Hosokawa M, Miyashita K. Seaweed carotenoid, fucoxanthin,

More information

untitled

untitled ver.2.0 JT. Cistanche Tubulosa (Schenk) R. Wight 1 16 2 2 6m 4 100 10 100 51 183 3 1 ver.2.0 JT GAP GMP 25% 9% 1. 2. GAP 2 ver.2.0 JT echinacosideacteoside 3 15 C 5 1) 2) 3) 4 4. 100 3. 1) 2005. 2) Haihui

More information

ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm

ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm 1 186 186 (1) - 192 (2) (ISAintrinsic sympathomimetic activity) 199 (3) ( MSAmembrane stabilizing activity) 2 (4) 21 (5) 212 (6) 216 (7) 219 (8) 224 (9) (ASL-8123) - 229 (1) d-esl l-esl - 231 2 235 235

More information

温泉の化学 1

温泉の化学 1 H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970

More information

後期化学_01_濃度

後期化学_01_濃度 2011 ( ) 1 4 1 100 g g % * 1 100 g 1 g 1 % * 2 (1 g)/(100 g) = 0.01 = 1 % 100 g 100 g 99 g 100 g 1 g 1 % 2.5 g 50 g (2.5 g)/(50 g) = 0.050 = 5.0 % 100 ml g 1 %(w/w) wt% % %(w/v) % / 2 % SI 2 / % 100 ml

More information

L- 11 12 13 15 15 17 17 18 21 23 25 25 27 29 29 30 31 32 32 33 36 36 36 37 37 37 38 39 39 40 42 42 45 46 48 10 48 11 49 11 50 50 50 51 51 51 51 52 52 53 53-54 12 55 55 57 28 3 6 4 8 7 6 100% 3 30 p.5760

More information

untitled

untitled POLYAMINE -P Ver.1.0 MM ver. 1.0MM POLYAMINE 1. 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504 (1983). 2) Ha.C. et

More information

20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine

More information

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12 (1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132

More information

研究成果報告書

研究成果報告書 21 4 25 peroxynitrite angiotensin II ETA MEK/ERK pathway endothelin-1 EDHF (EDHF) EDHF EDHF EDHF 2 [phosphodiesterase 3 (PDE3) cilostazol metformin thromboxane A2 ozagrel eicosapentaenoic acid (EPA) angiotensin

More information

報告書 H22-2A-09

報告書 H22-2A-09 061-0293 1757 TEL 0133-23-1211 2.0% 0.5% in vitro QOL Quality of Life 1 MCE-400 400 mpa s Duck Algin 350M M/G 0.8 70 80 C 20% 50 C 1.0% 5 C SV-10 5 C 10 ml E TV 20H model E 1 34 R24 1 ml 5 C 30 6 12 30

More information

研究成果報告書

研究成果報告書 Arterioscler Thromb Vasc Biol., 27, 2400 2406 (2007) J. Agri. Food Chem., 59, 4544 4552 (2011) Bioorg. Med. Chem. Lett., 21, 1786 1791 (2011) Advanced glycation end products (AGEs) AGEs AGEs AGEs HbA1c

More information

t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph

t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph 2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10

More information

<4D F736F F D F90858C6E5F C B B B838B>

<4D F736F F D F90858C6E5F C B B B838B> Isobutyl alcohol IUPAC 2-methylpropan-1-ol 2--1-2-Methyl-1-Propanol, Isobutanol CH 3 H 3 C OH CAS 78-83-1 C 4 H 10 O log P ow ( C) ( C) (kpa) (g/l) 74.12 74.14 1) -108 2) 108 2) 1.2 2) 87 2) 0.8 2) (74.1214)

More information

参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料)

参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料) 1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1

More information

2009年133巻3号3月号.indb

2009年133巻3号3月号.indb Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine

More information

% %

% % 4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5

More information

L- 19 L L- L-

L- 19 L L- L- 0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

untitled

untitled , Kaoru ARIYAMA 10 17N, Na, Mg,Al,Si,P,S,Cl,K,Ca,Fe,Cu,Zn,Se,Br,Rb Sr 14r2 0.9617 Tricholoma matsutake,,, JAS ICP-OESICP-MS 2ICP-OES ICP-MS,, Tricholoma matsutake -24- 1 7 2006 70 13 8 5 2,, 2007,, 10

More information

食糧 その科学と技術 No.48( )

食糧 その科学と技術 No.48( ) 79 +.* + 1/* A + 80, E + + Bioaccessibility +, 81,. 0* nm bo, Caco-, +* - - 82 - Caco, + Pow +, b-carotene ;,, a-carotene ; -, b-cryptoxanthin ;., lutein ; /, zeaxanthin ; 0, canthaxanthin ; 1, astaxanthin

More information

ライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12

ライフサイエンス関連 コラーゲン・ゼラチン製品案内 2015.12 3 mg/ml ph 3 4 8 1 Type I-A Type I-P Type I-A Type I-C Type III Type III Type IV Type IV TEL 072-820-3079 FAX 072-820-3095 4 8 4 Type I-A 20mL 1 F-12 MEM 5mL 1 4mL 5 10F-12MEM DFDME F-12 1 1199 5 DMERPMI-1640

More information

Table 1. Acute toxicity of Folin on mice. (Litchfield-Wilcoxon method) Numbers in parenthesis indicate 95% fiducial limits. Fig. 1. Analgesic effect of Folin on mice (1% acetic aid-induced writhing). Each

More information

gc-guide

gc-guide ...1...3 (Direct Injection)...5 OCI...7 PTV (...9 FID...11 ECD...13 AOC-20i/s...15...17...19 10 1 10 1 2µL 1µL 1mL 0.10.2mL He (He) 25cm/sec40cm/sec 30mL/min 1:501:100 Table Ex. Rtx-1, 515m :Ex. 100cm/sec

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

2 (FDA) 1 1 A D E K 1 LC UV 15 HPLC 3.5 UHPLC Agilent 12 Infinity LC Agilent 12 Infinity (G1311B) Agilent 12 Infinity (G13E) Agilent 12 Infinity (G131

2 (FDA) 1 1 A D E K 1 LC UV 15 HPLC 3.5 UHPLC Agilent 12 Infinity LC Agilent 12 Infinity (G1311B) Agilent 12 Infinity (G13E) Agilent 12 Infinity (G131 1 Agilent 12 Infinity 1 Siji Joseph Agilent Technologies, Inc. Bangalore, India 12 1 2 4 5 3 2 1 4 1 12 14 4 2 Agilent 12 Infinity 2 4 5 3 2.5 1. 1.5 2. 2.5 3. 2 (RP-HPLC) Agilent Poroshell EC-C1 Agilent

More information

a

a 1 a b c a b a 2 kg ms/cm 20 40 60 80 20 40 60 80 20 40 60 80 15 18 22 25 11 14 24 25 9 24 31 31 3? 32 32 26 33 33 33 33 33 30 29 30 14?? 21 28 9 16 22 26 11 16 22 24 11 14 17 15 10 11 22 25 7 12 26 30

More information

平成26年度 化学物質分析法開発報告書

平成26年度 化学物質分析法開発報告書 2,2-2,2 -Iminodiethanol Diethanol amine CAS 111-42-2 C 4 H 11 NO 2 105.1356-105.0790-28 C 1) 1.0881 g/cm 3 1)

More information

1999年3月作成(新様式第1版) 

1999年3月作成(新様式第1版)  200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1

More information

ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)

More information

Microsoft Word - 14_LCMS_アクリルアミド

Microsoft Word - 14_LCMS_アクリルアミド 3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)

More information

J. Jpn. Soc. Colour Mater., 79 [3], (2006) Anthocyanins : Structural Diversity, Color, and in Vivo Behavior Yuko NAKAGAWA, Takashi ICHIYANAGI,

J. Jpn. Soc. Colour Mater., 79 [3], (2006) Anthocyanins : Structural Diversity, Color, and in Vivo Behavior Yuko NAKAGAWA, Takashi ICHIYANAGI, J. Jpn. Soc. Colour Mater., 79 [3], 113-119 (2006) Anthocyanins : Structural Diversity, Color, and in Vivo Behavior Yuko NAKAGAWA, Takashi ICHIYANAGI, Tetsuya KONISHI and Seiichi MATSUGO J. Jpn. Soc. Colour

More information

1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4)

1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) 1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET ibalf ii CVF i iibalf i ii iiibalf i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) ET CVF (5) (6) 3) (1)in vitro 2. 1)ONO-5046Na (1) (2) (3) (4)

More information

平成26年度 化学物質分析法開発報告書

平成26年度 化学物質分析法開発報告書 2,2-2,2 -Iminodiethanol Diethanol amine CAS 111-42-2 C 4 H 11 NO 2 105.1356-105.0790-28 C 1) 1.0881 g/cm 3 1)

More information

水銀分析マニュアル

水銀分析マニュアル 1960 P197PHg 253.7 nm UV HgP0P 3 1 HgP2+P 253.7 nm 1 1.5 L/ 30 90 1 1 0.1 ng 50 ml 10 (10 cm ) HNOB3B HClOB4B HB2BSOB4B 1 1 5 200 230 30 P 1) 3 1 1 11 a HNOB3B HClOB4B 1 1 100 ml 100 ml HB2BSOB4B HCl 10%

More information

untitled

untitled CoQ10 CoQ10 CoQ10 CoQ10 CoQ10 (A CoQ10 CoQ10 B CoQ10 CoQ10 C CoQ10 CoQ10 CoQ10 QOL CoQ10 QOL CoQ10 CoQ10 CoQ10 CoQ10 14 還元型 CoQ10 の摂取はインフルエンザウイルス感染に対する予防効果を示す CoQ1050CoQ10 CoQ1080CoQ10 Åberg et al., Arch

More information

外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)

外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物) N- 1) 2) 1) GC/MS HPLC GC/MS 2) 0.01~0.05µg/l 0.5~50µg/kg GC/MS SIM GC/MS SIM GC/MS SIM a) b) -d 10 -d 10 -d 12 -d 12 c) d) 600 C 4 e) 1 99.999% f) a) b) - IX-1 - c) (ODS) 200-1,000mg 5ml 5ml 5ml d) e)

More information

橡99-24_00 アリルアルコール.PDF

橡99-24_00 アリルアルコール.PDF 1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log

More information

無印良品 2012 自転車 カタログ

無印良品 2012 自転車 カタログ 26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

More information

CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11

More information

2010 1 1 7 2 16 2 2 06in 3 3 錆 錆 06in 4 4 0.1 5 5 HCl Cl NaOH H Cl O 2 H H 2 O NaCl Na OH H 2 O NaCl 2010 6 6 ph3.0 30 mg/l 30 1 O-157 H7 2010 7 7 100 Cl 80 60 40 20 HClO ClO CL ph 10 100,000ppm 12 01

More information

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

More information

熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date Type URL Thesis or Di

熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date Type URL Thesis or Di 熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date 2008-03-25 Type URL Thesis or Dissertation http://hdl.handle.net/2298/9448 Right 1

More information

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

Ⅱ6.3界面活性剤

Ⅱ6.3界面活性剤 6.3 6.3.1 6.3.1 6.3.1.1 (1) (2) a) JIS K 0557 A3 b) JIS K 8891 c) (5g/L) d) (10g/L)JIS K 8576 1g 100mL e) (7+993)JIS K 8951 f) JIS K 8322 g) 0.1g 100mL 30mL 1L 500mL6.8mL 50g 1L h) 1L 500mL6.8mL 50g 1L

More information

2902 Shiraki et al., Aerosol and Air Quality Research, 17: , 2017 McLean, 1961; Schulman and Kilbourne, 1962; Moser et al., 1979; Knight, 198

2902 Shiraki et al., Aerosol and Air Quality Research, 17: , 2017 McLean, 1961; Schulman and Kilbourne, 1962; Moser et al., 1979; Knight, 198 PM 2.5 PM 2.5 UV-LED UV-LED 375 nm TiO 2 TiO 2 5 10 1 cm 200 5 ppm 9012.4 µmol h -1 1:2 2 25.43 µmol h -1 1 m 3 20 ppm 8 60 779 L A/PR/8/1934 H1N1 RNA 7 28 RNA PM2.5 TiO2 PM 2.5 VOC Hess et al., 2016;

More information

エディロールカプセルインタビューフォーム

エディロールカプセルインタビューフォーム 2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/

More information

untitled

untitled CH 2 H H H CH 2 n-1 H CH 2 n H Potato α-glucan phosphorylase H n soluble starch P i n-1 H P() 2 glucose-1-phosphate Pi H CBPase H glucose P i glucose-1-phospate cellobiose H cellooligosaccharide n+1 CDPase

More information

CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa

CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa 1 200117 21512 CAS 111693 110 NC(CH 2 ) 4 CN 1,4- C 6 H 8 N 2 108.14 1 99 2-1. 2 1 295 159 c.c. 550 3 1.7-4.9 20 d 0.965 4 3.73 = 1 0.3 Pa 0.002 mmhg20 2 log Pow-0.32 m/z 41, 1.0 68 0.54 54 0.43 4 Koc9-16

More information

CAS H 3 C C CH 2 C 9 H tert d = hpa

CAS H 3 C C CH 2 C 9 H tert d = hpa 1 200140 35 CAS 98839 1335-2- H 3 C C CH 2 C 9 H 10 118.18 1 99 4-tert- 1. 2-23.2 2 163164 2 54 574 3 0.96.6 20 d 4 0.9082 2 4.07 = 1 2.5 hpa 1.9 mmhg20 2 4 log Pow3.48 3.44 m/z 118, 1.0 103 0.58 91 0.21

More information

untitled

untitled 1 (1) (2) 1200 4200 2 2 3 2 1 44 20% 20056 VIPS VIPSSEICA SEICA () for for SEICA SEICA SEICA Web (EZwebJ-PCURL) Web OK 1700 BtoCBtoB XML Web OS: Windows 2000 Server Visual Studio.Net + C# SEICA H152 H148

More information

平成26年度 化学物質分析法開発報告書

平成26年度 化学物質分析法開発報告書 N,N- N,N-Dimethylacetamide Acethyldimethylamine CAS 127-19-5 C 4 H 9 NO 87.12 ~ 87.14 87.68413 163-165 C 1) - 18.59 C 2) 1 mg/l 25 C 3) 3.3 hpa 2 C 4) log P ow -.77 2).9429 2/4 C 1) 3.1 4) 1.31E - 8 atm-m

More information

CAS O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) % 2- A BHT , 4

CAS O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) % 2- A BHT , 4 2-1 9628 31307 CAS 117817 2- O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O 4 390.56 CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) 3 1 99 % 2- ABHT 1. 2-55 3 3, 4 386 171 350 6 0.1 % d 20 4 0.9861 4 13.48 0.30410-4 Pa 2.2810-7

More information

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)

More information

,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /

,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = / 1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5

More information

ボトックス注用

ボトックス注用 2018 5 21 2017 1220 5 8 7 1 2 2 9 50 100 22100AMX00488 22100AMX00489 2009 9 2009 9 2009 2 1997 4 2016 6 2018 5 1989 12 1A 2 1 2 3 2 4 5) 1 100 1 2 3 4 A 1 50 50 0 45mg 0 25mg 100 100 0 9mg 0 5mg A 1 4mL

More information

nsg02-13/ky045059301600033210

nsg02-13/ky045059301600033210 φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

More information

HPLC 1M KH 2 PO 4 ph ml Anthranilic acid: AnA 600 ml ml AnA 1.0 ml / min Anthranilic acid= PRESSURE 140 kgf / cm 2

HPLC 1M KH 2 PO 4 ph ml Anthranilic acid: AnA 600 ml ml AnA 1.0 ml / min Anthranilic acid= PRESSURE 140 kgf / cm 2 15 10-1-3. 1. HPLC 1M KH 2 PO 4 ph 3.0 50 ml Anthranilic acid: AnA 600 ml 1-1. 350 ml AnA 1.0 ml / min Anthranilic acid=137.14 PRESSURE140 kgf / cm 2 TOSOH TSK-GEL ODS- 80 Ts 1) mg / ml AnA in (φ4.6 250

More information

040202PC用.doc

040202PC用.doc 15 48 15 8 25 15 1321 15 8 25 0825002 15 8 25 6 8 15 2 18 15 6 27 2 15 3 13 28 35 (1) 51 198 7 (2) 3 6 1 100g (1) 1 (1) 1 2 1 astaxanthin;3,3 -dihydroxy-, -carotene-4,4 -dione (2) 1 2 C40H52O4 596.86 97.0

More information

< B C957491E48E86312E696E6464>

< B C957491E48E86312E696E6464> 10 DDS New York Academy Renal Biochemistry (Elsevier) Glutathione (John Wiley & Sons) Antioxidants in Therapy and Preventive Medicine (Plenum) The Liver: Biology and Pathophysiology (Raven Press) NO SSC

More information

54 Sample Handling NEW Centrifuge 5910 R 5910 R ml MULTI PURPOSE CENTRIFUGES ml 50 ml 2. > 58xx > ml / ml / 120 5/7

54 Sample Handling NEW Centrifuge 5910 R 5910 R ml MULTI PURPOSE CENTRIFUGES ml 50 ml 2. > 58xx > ml / ml / 120 5/7 54 NEW Centrifuge 5910 R 5910 R 4 750 ml 1+2 5 3 6 1. 15 ml 50 ml 2. > 58xx > 4 750 ml / 36 50 ml / 120 5/7 ml / 20 MTP 3. > > 5 4. > 5910 R 5. > ECO 2019 55 > 0.2 ml 750 ml > MTP PCR Deepwell > 0.2 ml

More information

寄稿論文 規則性無機ナノ空間が創り出す新しい触媒能 | 東京化成工業

寄稿論文 規則性無機ナノ空間が創り出す新しい触媒能 | 東京化成工業 MCM-41 M41 MCM-41 M41 2 3 m 2 /g nm nm Mn Ti Ti H N 2 S Ti-MCM-41, H H N H H 2 2 -Urea, CH 2 Cl 2, H 2 S + S 1b 2b 3b 54%, 58% ee Ti M41 H 2 As 4 ZP 4 ZP ZS ZS 5 Me Me Me Me M41 / 15 mg MeH 1.0 mmol 89%

More information

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

More information

48 13 13 13 38 21 13 3 13 3.1 l l l l l l 4.1.1 5mm 0.5mm 5mm 10 500mL 500mL 500mL 20 1 200 / 4 5 6 3000G 20 G1118 R N 2 10-8 GG Rcm Nrpm 1μm 2 3000G 1 /1 4.1.2PCB PCB 5mm 0.5mm 5mm 10 500mL 500mL 500mL

More information

能書単頁9[1].5(2)

能書単頁9[1].5(2) ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c

More information

,798 14, kg ,560 10, kg ,650 2, kg ,400 19, kg ,

,798 14, kg ,560 10, kg ,650 2, kg ,400 19, kg , / HS / TEL FAX 2007 1 18,000 9,540.00 0.53 kg 2007 1 99,000 38,518.00 0.39 kg 2007 1 30,200 11,778.00 0.39 kg 2007 1 15,000 5,565.00 0.37 kg 2007 1 21,000 7,400.00 0.35 kg 2007 1 40,000 20,579.00 0.51

More information

Ethanol Preconditioning (EPC) enos(cgrp) 1 Korthuis RJ Medical Pharmacology and Physiology University of Mi

Ethanol Preconditioning (EPC) enos(cgrp) 1 Korthuis RJ Medical Pharmacology and Physiology University of Mi (9:40 9:50) (9:50 10:30) O-01 1 2 2 2 2 2 2 2 2 2 3 3 4 4 1 2 3 4 O-02 15-deoxy-Δ 12,14 -PGJ 2 Heme oxygenase-1(ho-1) 1 2 3 3 3 3 3 3 1 1 5 4 3 2 3 4 5 O-03 C hepcidin 1 1 1 1 1 1 1 1 1 2 2 2 2 1 2 O-04

More information

- 108 -

- 108 - 3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg

More information

2007 Vol.56 No.6 総説 丸山浩樹

2007 Vol.56 No.6 総説 丸山浩樹 Reprinted from RADIOISOTOPES, Vol.56,.6 June 2007 Japan Radioisotope Association http : //www.jrias.or.jp/ α β α β ε m z α µ µ α m z m z µ µ Curr. Opin. Biotechnol J. Proteome Res Rapid Commun. Mass

More information

50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH

50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH 3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-

More information

Vol.42 No.1/◇0 目次[三]3.2

Vol.42 No.1/◇0 目次[三]3.2 Department of Applied Biology and Chemistry, Faculty of Applied Bioscience, Tokyo University of Agriculture, 1 1 1, Sakuragaoka, Setagaya-ku, Tokyo 156 8502 Hitachi Health Management Center, 4 3 16, Osecho,

More information

23 3 11 21 24 28 4 31,371 20,822 34,511 21,720 12,278 9,574 7,502 137,778 1 69 83.49% 70 15.55% 0.96 3.61% 40 1.19% 1055 29.65% 28 10 1 2 230,250 43,150 656 138,000 137,832 137,820 121,000 30,000 246,800

More information

untitled

untitled -1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86

More information

- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17-54 55 56 57 58 ( ) 54 7 55 56 57 58 10 54 55 57 58 56 25 27 25 27 20 22 25 22 1.4g 23 23 :1.8g

More information

untitled

untitled 26 3 31 BDF BDF BDF FAME BDF BDF BDF BDF BDF BDF BDF BDF BDF FAME BDF BDF 80.0 97.0% BDF 120 330 0.8% 2.2% 1. 1 1-1 1 1-2 1 2. 2 2-1 2 2-2 5 2-3 6 3. BDF 7 3-1 7 3-2 7 3-3 14 3-4 JOY 21 3-5 32 3-6 39 3-7

More information

xxxxEN.qxd

xxxxEN.qxd Ultron ES-VM : HPLC HPLC 28,000, 1-120Å 5-µm Ultron ES-VM [1-] Ultron ES-VM HPLC ph pi 3.8 4.3 Ultron ES-VM ph pi ph pka = 4.4 ph 3.0 6.0 pka = 4.0 9.2 k' 1 αph 1 Ibuprofen H3 C CHCH 2 CH CH H 3 C Chlorpheniramine

More information

2007050781......_.L.O...z.W

2007050781......_.L.O...z.W a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab

More information

untitled

untitled 27.2.9 TOF-SIMS SIMS TOF-SIMS SIMS Mass Spectrometer ABCDE + ABC+ DE + Primary Ions: 1 12 ions/cm 2 Molecular Fragmentation Region ABCDE ABCDE 1 15 atoms/cm 2 Molecular Desorption Region Why TOF-SIMS?

More information